Master’s studies

Drug Safety and Pharmacovigilance 2017/2018 (7.5 credits)

Autumn 2017 weeks 44-02 (November - mid-January) - Mixed - 50 % - Distance learning

Application Deadline: 2017-04-18

Enrolment Code: UU-38501 Application

Language of Instruction: English

Location: Flexible

Selection: Higher education credits

Outline for distance course: The course is entirely web-based and contains no compulsory campus meetings. Lectures are recorded and organised as video/audio sessions and are available on a web-based teaching platform. The students are offered supervised studies via the same teaching platform. This platform is also used for individual assignments, group exercises and discussions. Some of these assignments and exercises are mandatory and the participants are offered general or individual feedback on these moments. The participants and teachers communicate via the website and via e-mail. A forum for discussion is also available. Examination will be in the form of web-based tests or individual assignments. In order to participate in this course you must have access to a computer with a rapid Internet connection, headset with microphone and programs such as Adobe Flash/Connect have to be installed.

Spring 2018 weeks 12-22 (mid-March - June) - Mixed - 50 % - Distance learning

Application Deadline: 2017-10-16

Enrolment Code: UU-88501 Application

Language of Instruction: English

Location: Flexible

Selection: Higher education credits

Outline for distance course: The course is entirely web-based and contains no compulsory campus meetings. Lectures are recorded and organised as video/audio sessions and are available on a web-based teaching platform. The students are offered supervised studies via the same teaching platform. This platform is also used for individual assignments, group exercises and discussions. Some of these assignments and exercises are mandatory and the participants are offered general or individual feedback on these moments. The participants and teachers communicate via the website and via e-mail. A forum for discussion is also available. Examination will be in the form of web-based tests or individual assignments. In order to participate in this course you must have access to a computer with a rapid Internet connection, headset with microphone and programs such as Adobe Flash/Connect have to be installed.

Entry Requirements: Optional 2,5 credits from Preclinical Safety Assessment and Pharmacovigilance, or Adverse Drug Reactions and Pharmacovigilance, 7.5 credits

Fees:

If you are not a citizen of a European Union (EU) or European Economic Area (EEA) country, or Switzerland, you are required to pay application or tuition fees. Formal exchange students will be exempted from tuition fees, as well as the application fee. Read more about fees.

Application Fee: SEK 900

Tuition fee, first semester: SEK 18125

Tuition fee, total: SEK 18125

Please note: The course is given in collaboration with the Uppsala Monitoring Centre (UMC). UMC is responsible for the management of the WHO Programme for International Drug Monitoring and the WHO Global ICSR Database.

About the course:

This is a continuation course based on the same format as the introductory course (Preclinical Safety Assessment and Pharmacovigilance) but a more comprehensive textbook will be used. We will discuss the principles of risk/benefit profiling of drugs and the safe use of medicines. The course is suitable for those who want to work with adverse drug event reporting and drug safety.

We appreciate that you are considering an application to this course. Please make sure that you understand the general and course-specific entry requirements before you apply. You must have passed  2,5 credits in our introductory course Preclinical Safety Assessment and Pharmacovigilance (3FX011 alt. 3FX211) or the entire campus course 3FX200 in order to be eligible for this continuation course. 

The course will focus on

  • The importance of pharmacogenomics for individual variation in adverse drug reactions
  • Serious adverse drug reactions
  • Risk communication
  • Risk/benefit profiling of pharmaceutical drugs especially biologicals
  • Adverse event reporting and methods in pharmacovigilance
The course is given in collaboration with the Uppsala Monitoring Centre, WHO. Please note that the course does not cover the detailed pharmacovigilance guidelines or regulations set up by EMA and FDA or the web-based pharmacovigilance tools set up by these agencies. Furthermore, the course will not cover detailed regulations for adverse event reporting within pharmaceutical companies.

More information

Contact

Department of Pharmaceutical Biosciences

Uppsala biomedicinska centrum BMC, Husarg. 3

Box 591, 751 24 UPPSALA

Telephone: 018-471 4010